Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
European Journal of Cancer, 06/15/09
Vergote I et al. - Canfosfamide HCl (CAN; a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis) was well tolerated in pts with platinum-refractory or -resistant ovarian cancer (OC).
Methods- Pts with platinum-refractory or -resistant OC who had progressed on second-line therapy with pegylated liposomal doxorubicin (PLD) or topotecan (TOPO), were randomized to:
- CAN 1000 mg/m2 IV q 3 weeks or
- Either PLD 50 mg/m2 IV q 4 wks or TOPO 1.5 mg/m2 IV d1-5 q 3 wks
- 461 pts were randomised after stratification for ECOG performance status, prior therapy, and bulky (>5 cm) disease
- Groups were well balanced
- In the control arm 58% and 42% were treated with PLD and TOPO, respectively
- CAN was well tolerated with the most common grade 3-4 toxicities of 5% anaemia, 4% neutropaenia (no febrile neutropaenia), 4% thrombocytopaenia, and 7% vomiting
- PFS and OS were higher in the control arm
- In a subgroup analysis PFS and OS were higher with PLD than with TOPO
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Adjuvant radiotherapy and chemoradiation after surgery for cervical cancer
Cochrane Reviews, 10/09/09
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Annals of Internal Medicine, 10/20/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Nonsteroidal anti-inflammatory drugs
Cancer, 10/16/09
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Sponsor
Article Search
Sponsor
Sponsor